FindTrial
Sign In

Clinical aspects of Clostridium difficile infection after initiation of anti tuberculous medication

Clinical aspects of Clostridium difficile infection after initiation of anti tuberculous medication

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0000808
Enrollment
50
Registered
2013-07-26
Start date
2013-06-12
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Konyang University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Clostridium difficile infection patients who were administrated anti-TB medications Definition of CDI : Documented diarrhea and any positive outcome ( one or more) in the following diagnostic tests. CD toxin A and/or B by enzyme immunoassay (EIA) Positive stool culture for C.difficile Typical endoscopic findings, such as multiple white or yellow plaques

Exclusion criteria

Exclusion criteria: Patients who has not been recorded variables. Patients who has been administered any antibioitcs (except anti-TB medications), within a month from the start of CDI. Patients who follow up loss

Design outcomes

Primary

MeasureTime frame
Incidence of C.difficile infection after TB medication;Association between C. difficile infection and rifampicin—

Secondary

MeasureTime frame
clinical manifestations, lab findings, imaging findins—

Countries

Korea, Republic of

Contacts

Public ContactYumi Lee

Konyang University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026